CASE PRESENTATION ALIREZA SADEGHI MD. General Surgery Service Kings County Medical Center October 6 th 2006
|
|
- Clare Rosaline Jordan
- 5 years ago
- Views:
Transcription
1 CASE PRESENTATION ALIREZA SADEGHI MD General Surgery Service Kings County Medical Center October 6 th 2006
2 ACGME Core Competencies 1) Medical Knowledge 2) Patient Care 3) Interpersonal & Communication Skills 4) Practice Based Learning 5) Systems Based Practice 6) Professionalism
3 ACGME: 1,2 Case Presentation 57 year old African-American Female presented to Kings County ED on 8/17 with chief complaint of abdominal pain for 10 weeks Associated complaints 20 lbs weight loss over 3 months Progressive abdominal distention Early satiety & Postprandial vomiting Denied fever/chills, diarrhea, constipation, hematemesis or hematochezia
4 ACGME: 1,2 Case Presentation Medical History: Denies any medical or surgical history No outpatient medications & NKDA Afebrile, Stable vitals Admission Labs: CBC: 7.6/12.2/39.2/482 Chem:137/4.7/102/24/9/0.9/82 LFTs: AlkPhos 208 T.Bili 0.5 Coags: 12.6/21/1.1
5 ACGME: 1,2,4,6 Case Presentation Physical Exam: Awake & Alert, NAD Chest: CTA B/L RRR S 1 &S 2 present, No murmurs Abdomen: Soft, markedly distended, voluntary guarding, no rebound, distant bowel sounds. Palpable and firm abdominal mass in all quadrants Non-pulsatile and immobile Rectal: Guiac Negative
6 Case Presentation Previously presented to Kings County ED on 6 weeks prior with similar complaints Had imaging studies Was seen by GYN service & was followed up as outpatient by GYN Dx: Ovarian Mass CA 125: Elevated AFP, CEA: Normal
7
8
9
10
11
12
13
14
15
16
17
18
19 ACGME: 1,2,4,6 Case Presentation Diagnosis: Large abdominal mass Gastrointestinal Stromal Tumor Pancreatic Cystadenoma/Cystadenocarcinoma Pancreatic Cyst/Pseudocyst
20 ACGME: 1,2,3,4,5,6 Case Presentation Operative Course: 08/20/06 Exploratory Laparotomy: R2 Resection Unable to explore abdomen due to size of tumor Controlled entry into the tumor Removal of >3 liters of necrotic fluid En-bloc resection of greater curvature of stomach along with the mass and the mid transverse colon Palpable lesion in segment 3 of liver Wedge resection Omentectomy
21 ACGME: 1,2,3,4,5,6
22
23
24
25 ACGME: 3,5,6 Pathology Abdominal mass: Portion of stomach with malignant gastrointestinal stromal tumor, partially cystic with ulceration. Necrosis seen. High mitotic figures noted. Resection margins are negative for tumor. Transverse colon: Negative for tumor Omentum: Metastatic tumor present. Liver: Metastatic GIST. Negative resection margins. Note: Immunohistochemistry for CD117 & CD34 is positive.
26
27
28
29
30 CD117 CD34
31 ACGME: 1,2,3,4,5,6 Case Presentation Postoperative Course: Patient experienced delayed gastric emptying with high NGT outputs for 7 days Responded to Prokinetics NGT removed on POD 8 Patient tolerated regular diet by POD 13. Patient seen by Oncology Service Started on Gleevec 400mg Once Daily Patient discharged on POD 14. Follow up in 3 months with imaging.
32 Gastrointestinal Stromal Tumors From Biology & Pathology to the GIST of Targeted Cancer Therapy ALIREZA SADEGHI MD University Hospital Brooklyn Downstate Medical Center Kings County Hospital Center October 6 th 2006
33 ACGME: 5 Historical Overview s (GIST = Smooth Muscle Tumor) On the basis of Light Microscopy Stromal Tumors of the GI tract thought to be neoplasms of smooth muscle cell origin Leiomyoma, Leiomyosarcoma or Leiomyoblastomas s On the basis of Electron Microscopy & Immunohistochemistry studies in early 1980s Inconsistent evidence of smooth muscle differentiation Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
34 Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
35 ACGME: 5 Historical Overview Inconsistent Evidence: Expression of Actins & Desmin found to be variable compared to those in smooth muscle neoplasms arising from the myometrium or blood vessel walls Subset of Stromal Tumors stained positively for neural crest markers not present in smooth muscle neoplasms S100, Neuron-specific Enolase, PGP9.5 Gastrointestinal Autonomic Nerve Tumors (GANT) Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
36 ACGME: 5 Historical Overview Origin of Stromal Tumor Mazur & Clark (1983) Introduced the term Stromal Tumor in recognition of the distinct clinical & pathological presentation of these tumor Mikael et al (1994) Demonstrated the expression of CD34 on GISTs Poor specificity (~70%) The term and entity of Gastrointestinal Stromal Tumor was widely accepted in the late 90s. Any Mesenchymal tumor of the GI tract. Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
37 ACGME: 5 Origin of GIST Controversy to the line of differentiation: Myogenic Phenotypes Neural differentiation Mixed differentiation Null Phenotype Hirota et al. Science 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Separation of GIST from other GI Mesenchymal Tumors True GIST definition is Born Hirota et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-80
38 ACGME: 5 Origin of GIST Definition of GIST Mesenchymal tumors affecting the entire GI tract Express the KIT Protein CD117: Stem cell factor receptor detected by immunohistochemistry Three types: Cellular Spindle Cell Epitheloid Pleomorphic (combination of spindle & epitheliod) Exclusion of true smooth muscle tumors, schwannomas and neurofibromas Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
39 ACGME: 5 Origin of GIST Definition of GIST Up to now positive immunoreactivity for KIT has been regarded as the definition for GISTs. Recently, it has become apparent that some GISTs that lacked c-kit mutations were found to have activating mutations of platelet derived growth factor receptor (PDGFRα). Revised Definition: GISTs now encompass Mesenchymal Tumors that express KIT protein or have activating mutations of receptor tyrosine kinase genes (c-kit or platelet derived growth factor receptor alpha (PDGFRα)). Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
40 Cell of Origin Histogenesis: Suggests that GISTs originate from Interstitial Cell of Cajal (ICC) or A primitive stem cell that differentiates towards both the ICC & smooth muscle phenotype. The ICCs are intercalated between the autonomic nerves & smooth muscle cells. Their principal function is to generate autonomous rhythmic contractions, involved in digestion & peristalsis. GI pacemaker cells Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
41 ACGME: 5 Cell of Origin Immunohistochemical studies GISTs have similar features to ICC Both positive with CD34 & CD117 and negative for other neural and smooth muscle markers. GISTs arise from organs in which ICC are present including Stomach, Small Bowel, Colon, Rectum, Oral Cavity, Biliary Tree, Omentum & Liver Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
42 Interstitial Cells of Cajal
43 Spanish Histologist Who is Cajal? Pioneering work on the fine structure of the nervous system in the Spanish universities In 1889 he discovered the mechanisms governing the morphology & connective processes of nerve cells in the gray matter of the CNS. First to isolate the nerve cells, called Cajal's cells, that are located near the surface of the brain. For his work in this field Cajal shared the 1906 Nobel Prize in physiology & medicine with the Italian cytologist Camillo Golgi. Santiago Ramón y Cajal ( ) Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
44 The Phenotypic Marker KIT Tyrosine Kinase (CD117) Phenotypic Marker of Most GISTs The c-kit proto-oncogene is located on the long arm of chromosome 4 Encodes a trans membrane TK Receptor KIT protein consists of an extra cellular ligand-binding site and an intracellular kinase domain The ligand for KIT is a growth factor called the stem cell factor (SCF) KIT-SCF axis is essential to the development of ICC ICC fails to develop if either factor is missing Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
45 Tyrosine Kinase Membrane Receptor Families
46 Tyrosine Kinase Membrane Receptor Families Epidermal Growth Factor Receptor & Family
47 Tyrosine Kinase Membrane Receptor Families Insulin Receptor & Family
48 Tyrosine Kinase Membrane Receptor Families Platelet-Derived Growth Factor Receptor& Family including KIT
49 Tyrosine Kinase Membrane Receptor Families Vascular Endothelial Growth Factor Receptor & Family
50 Tyrosine Kinase Membrane Receptor Families Fibroblast Growth Factor Receptor & Family
51 Tyrosine Kinase Membrane Receptor Families Hepatocyte Growth Factor Receptor & Family
52 The Phenotypic Marker Extra cellular binding of stem cell factor results in dimerization of the receptor, triggering phosphorylation of the kinase domain. Induces a signaling cascade that propagates through the cytoplasm into the nucleus which affects many aspects of cellular behavior including proliferation, differentiation, adhesion & apoptosis Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
53 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Inactive Receptor
54 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Receptor Dimerization
55 TK Receptor Activation and Signal Transduction Extracellular Intracellular P P P P P P Receptor Auto-Phosphorylation & Activation
56 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular P P P P P P
57 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Y Intracellular Signaling Molecule P P P P P P
58 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Y P P Y P P P P Recruitment & Phosphorylation of Signaling Molecule
59 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Y P P Y P P P P ATP ADP Recruitment & Phosphorylation of Signaling Molecule
60 TK Receptor Activation and Signal Transduction Ligand Extracellular Intracellular Y P P Y P P Y P ATP P P ADP Activation of Signaling Molecule & downstream Signaling Pathway
61 ACGME: 5 KIT Gain-Of-Function Mutations The most common mutations are in the Juxtamembrane region in exon 11, resulting in ligand-independent activation of tyrosine kinase Exon 9 (extracellular domain) Exon 13 (kinase domain) Exon 17 (phosphotransferase domain) Around 10 15% of GISTs lack KIT expression Within this group a large subset have gain of function mutations of PDGFRα Mutations in PDGFRα provide an alternative mechanism in GIST oncogenesis Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
62 ACGME: 5 KIT Gain-Of-Function Mutations These mutations result in: Auto-phosphorylation of c-kit Ligand-independent tyrosine kinase activity Stimulation of downstream signaling pathways leading to uncontrolled cell proliferation Other activating mutations in Kit exist Germ Cell Tumors Myleofibrosis, CML & Mastocytosis Corless CL et al. Biology of Gastrointestinal Stromal Tumors. J Clin Oncol (2004) 22;
63 ACGME: 5 Epidemiology & Risk Factors Incidence of GISTs 10-20/million persons/yr for symptomatic tumors 20-30% Malignant 3% GI tract Neoplasms / 5 % of all sarcomas 80 % of gastrointestinal mesenchymal tumors Occur in older individuals over 50 years of age Median age 60; Rare before age of 40 No gender preference (M>F?) Carney s (F): Gastric GIST, Pulmonary Chondroma & Paraganglioma No known risk factors for the disease Genetic influence has been described Von Recklinghausen s disease Perez EA et al. Current Incidence and outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Tumors. J AM Coll Surg 2006;202: Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
64 ACGME: 5 Changing Incidence University of Miami Experience: Age & population-adjusted gastrointestinal mesenchymal tumor incidence. 13 center tumor registry: NCI (17% US population) Cancer cases in Florida since 1981 (2 million cases) Perez EA et al. Current Incidence and outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Tumors. J AM Coll Surg 2006;202:
65 ACGME: 5 Anatomic Locations & Age Perez EA et al. Current Incidence and outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Tumors. J AM Coll Surg 2006;202:
66 ACGME: 5 Anatomic Locations & Incidence of Localized Disease at Presentation Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
67 Pathology Gross Features GISTs range in size from several millimeters to over 30 cm Most lesions are well circumscribed & unencapsulated Some are multi-nodular or may have a fleshy appearance Areas of hemorrhage, cystic degeneration & central necrosis may be seen GISTs tend to be primarily intramural tumors Usually involving the submucosa & muscularis propria Large tumors may have a dumbbell appearance with the tumor protruding both into the lumen & from the serosa Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
68 Pathology Microscopic Features Spindle cell type (70%)
69 Spindle-cell tumor with High mitotic rate
70 Pathology Microscopic Features Epithelioid type (20%) more commonly kit negative found in omentum & mesentery
71
72 Pathology Microscopic Features Mixed type (5%) & Pleomorphic type (5%)
73 ACGME: 5 Immunohistochemistry: Essential for making the diagnosis
74 ACGME: 5 Clinical Presentation Spectrum Clinically low risk tumor high risk tumor GISTs can occur at any level of the GI tract Symptoms vary according to the size and location Small asymptomatic tumors found incidentally (< 1cm) Laparotomy, Endoscopy or radiological studies for other conditions Symptomatic tumors: Abdominal discomfort Ulcerate and present as GI bleeding Hemorrhage into peritoneal cavity from tumor rupture Lesions may derive blood supply from contiguous organs & detach from stomach Lesions in the esophagus may present with dysphagia Intestinal neoplasms may present with abdominal mass, obstruction or perforation Some patients present with metastases, particularly to the liver Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
75 ACGME: 5 Risk of Malignant Behavior Consensus guidelines NIH/NCI Workshop April 2001 Tumor Size 5 yr survival» >10 cm 20%» <5 cm 60% Mitotic Index Location Gastric primary fare better than SB/Rectal Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
76 ACGME: 5 Surgical Resection: Primary GIST DeMatteo: MSKCC DeMatteo RP. The GIST of Targeted Cancer Therapy: A Tumor (Gastrointestinal Stromal Tumor), a Mutated Gene (c-kit), and a Molecular Inhibitor (STI571). Ann Surg Oncol, 9(9) 2002;
77 ACGME: 5 Metastasis Up to 30% of newly diagnosed GISTs Overtly Malignant Progression Recurrence at site of resection Intra-abdominal spread Liver metastasis LN mets & extra-abdominal disease are uncommon Recurrence occurs as well with Low Malignant Potential GISTs: up to 10 yrs. Sabah M et al. Gastrointestinal stromal tumors an update. Current Diagnostic Pathology (2005) 11;
78 ACGME: 5 Classification System In recent years, it has become clear that GISTs require site evaluation because of differing behavior It has been suggested that the site of the tumor is a prognostic factor independent of the tumor size & mitotic count with small bowel tumors having the worst prognosis Miettinen M et al. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch (2001) 438:1-12
79 ACGME: 5 Prognostic Factors Tumor stage at presentation Presence of Liver or Peritoneal Metastasis Bad outcome Tumor size, site & mitotic activity Incomplete resection margins Tumor Rupture (Pre or Intra-operatively) Epitheloid Variant Aggressive behavior in Small Bowel Mucosal Invasion Poor outcome Cellularity Proliferation Markers (ki-67) Miettinen M et al. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch (2001) 438:1-12
80 ACGME: 5 GIST Rupture Perforation or tumor rupture & incomplete tumor resection Associated with a significantly reduced disease-free & overall survival 5-yr survival rate: 54% Complete Resection 5-yr survival rate: 9% Incomplete Resection Tumor rupture eliminates the survival advantage conferred by complete resection of a primary GIST It reduces the median survival from 46 to 17 months which is comparable to the median survival after incomplete resection» ~20 Months Perez EA et al. Current Incidence and outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Tumors. J AM Coll Surg 2006;202:
81 ACGME: 5 Imaging X-ray /CT Scan / Gastrograffin Studies / MRI / US & EUS / Endoscopy Lau et al. Imaging of gastrointestinal stromal tumor (GIST). Clinical Radiology (2004) 59;
82 Imaging
83 Imaging
84 Imaging
85 Imaging
86 Imaging Lau et al. Imaging of gastrointestinal stromal tumor (GIST). Clinical Radiology (2004) 59;
87 Treatment Options Surgical Resection Adjuvant Chemotherapy Radiotherapy Molecular Target Therapy Imatinib Mesylate / STI571 (Gleevec ) Tyrosine Kinase Inhibitor Neoadjuvant vs. Adjuvant role in Primary & Recurrent/Metastatic GISTs
88 Clinical Trials Gleevec What is the right dose? Duration of therapy? Adjuvant therapy? Neo-adjuvant therapy? Influence of mutations on response to therapy? Role of surgery in recurrence?
89 ACGME: 5 What is Gleevec? Formally known as STI-571 Molecular Formula C 29 H 31 N 7 O CH 4 SO 3 Manufactured Novartis Pharmaceutical FDA approval just after 32 months after the first dose Fastest approval by FDA of all cancer drugs in history Contains Imatinib Mesylate Jean-Pierre et al. The effect of Surgery and Grade on Outcome of Gastrointestinal Stromal Tumors. Arch Surg. 2001; 136:
90 PROMOTES APOPTOSIS
91 ACGME: 5 Introduction of Gleevec: February 2000: Finland First patient with metastatic GIST was treated with Gleevec Previously failed a variety of therapies Therapy produced a rapid partial response Dramatic reduction in tumor size on CT scan & tumor uptake on PET scan Subsequent complete surgical resection Histology: Myxoid degeneration of GIST Bauer et al. Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors, Critical Reviews in Oncology/Hematology (2006), doi: /j.critrevonc
92 ACGME: 5 Outcome DeMatteo RP. The GIST of Targeted Cancer Therapy: A Tumor (Gastrointestinal Stromal Tumor), a Mutated Gene (c-kit), and a Molecular Inhibitor (STI571). Ann Surg Oncol, 9(9) 2002;
93 ACGME: 5 Timeline of Gleevec Development DeMatteo RP. The GIST of Targeted Cancer Therapy: A Tumor (Gastrointestinal Stromal Tumor), a Mutated Gene (c-kit), and a Molecular Inhibitor (STI571). Ann Surg Oncol, 9(9) 2002;
94 Treatment Options Treatment of Primary GIST Surgical Resection Adjuvant Therapy: Gleevec? VS.
95 Principal Treatment of Primary GIST: Surgical Resection Resection: Complete tumor resection can be accomplished in 40% - 60% of all patients who have GIST >70% of those who have primary nonmetastatic disease Fragile, especially if large with extensive hemorrhage or necrosis Avoid uncontrolled rupture of tumor Preoperative biopsy not recommended Avoid risk of rupture, bleeding or tumor extravasation Associated with poor prognosis Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004; ACGME: 5
96 ACGME: 5 Surgical Resection: Primary GIST Only wedge/segmental resection of underlying organ Protrude from tissue of origin & displace surrounding structure Non-Invasive (unlike intra-abdominal malignancies) Negative resection margins only for small tumors No Lymphadenectomy required Resect all organs en bloc to avoid spillage Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
97 ACGME: 5 Surgical Resection: Primary GIST Memorial Sloan-Kettering Cancer Center DeMatteo et al prospective study of 200 patients 93/200 presented with Primary Tumor & No Mets 80 underwent complete surgical resection 5 year survival 54% Similar to survival at MD Anderson CC Trial Median survival 5 months with incomplete resection of recurrent & metastatic 10 months with incomplete resection of metastatic lesion 16 months with complete resection of metastatic lesion 54 months with complete resection of locally recurrent disease Bauer et al. Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors, Critical Reviews in Oncology/Hematology (2006), doi: /j.critrevonc DeMatteo RP et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-8.
98 ACGME: 5 Surgical Resection: Primary GIST Outcomes Long-term follow up for high-risk GISTs Surgery alone is not curative Local recurrences / Metastasis develop in 50-90% of patients with initial curative resection Median Time to Recurrence: ~ months 5 yr survival: % 10 yr survival: % Median Survival: 5 yrs Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
99 ACGME: 5 Treatment Options Treatment of Metastatic/Recurrent GIST Surgery Conventional Chemotherapy/Intraperitoneal Chemotherapy Radiotherapy: Palliation STI571 (Gleevec) Outcomes before Gleevec Median survival ranged from 6-18 month Recurrence was the rule after resection of primary tumor Up to 90% had an adverse outcome (recurrence, metastasis or death) Outcomes after Gleevec Median survival improved to > 24 months Survival to 68 months after Gleevec & Aggressive surgical resection Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005)
100 ACGME: 5 Outcomes Introduction of Gleevec Perez EA et al. Current Incidence and outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Tumors. J Am Coll Surg 2006;202:
101 ACGME: 5 Rational For Resection Short term: Elimination of pain & risk of rupture and hemorrhage Long term: Gleevec: Lesser risk of tumor recurrence through emergence of resistant clones Cytoreduction by decreasing volume & vascularity Less radical resections with less morbidity Tumor may under go myxoid/hyaline changes Barnes G et al. A review of the surgical management of metastatic gastrointestinal stromal tumours(gists) on imatinib mesylate (Glivec). International Journal of Surgery (2005) 3;
102 Pre & Post Gleevec Lau et al. Imaging of gastrointestinal stromal tumor (GIST). Clinical Radiology (2004) 59;
103 ACGME: 5 Surgical Options: Metastatic/Recurrent GIST Incidence of recurrence after complete curative resection M.D. Anderson Cancer Center Series 13/132 (10%) remained disease free after 68 months of follow up Median time to recurrence ~ 2 years Site of recurrence: Abdomen MSKCC Series First site of recurrence is typically Peritoneum (50%) 66% also had Liver involvement Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005)
104 ACGME: 5 Surgical Options: Metastatic/Recurrent GIST Results of surgical management of recurrence or spread In patients whose primary tumor is a very-low-risk or rectal/anal GISTs Locally recurrent disease has been treated successfully with total excision without further recurrence for 4-10 years. Clary et al studied 239 GISTs Analysis outcomes after resection of primary, recurrent, or metastatic Complete resection improved disease-specific survival in all cases: 96 versus 26 months for primary disease 49 versus 8 months for locally recurrent disease 39 versus 11 months for metastatic disease Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
105 ACGME: 5 Surgical Options: Metastatic/Recurrent GIST Mudan et al reported a median survival of 15 months after surgery for recurrent GIST The longest survival was observed in patients whose recurrence consisted of hepatic metastasis alone Hepatic Metastasectomy The only significant determinant of survival the duration of the DFP between initial surgery & recurrence An indicator of the biologic aggressiveness of the tumor Unfortunately, resection of recurrent peritoneal GIST is seldom curative, even when all gross tumor is removed Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004; Mudan SS et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7.
106 ACGME: 5 Chemotherapy: Metastatic/Recurrent Disease Before the introduction of STI571 GISTs notoriously refractory to conventional chemotherapy Edmonson et al Trial of dacarbazine, mitomycin, doxorubicin & cisplatin Enrolled two cohorts of patients: Leiomyosarcomas vs. GISTs Response rates:» 54% in leiomyosarcomas vs. 4.9% in GISTs Doxorubicin and ifosfamide (0-27%) Paclitaxel (7%) Gemcitabine (0%) Response rates: poor survival of patients with metastatic disease Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
107 ACGME: 5 Chemotherapy: Metastatic/Recurrent Disease Before the introduction of STI571 Eilber et al at UCLA studied adjuvant intraperitoneal chemotherapy using mitoxantrone for treating peritoneal recurrence The median time to subsequent recurrence after therapy in patients who had disease isolated to the peritoneum from 8 months in 8 pts who had surgery alone 21 months in 19 pts who had surgery & intraperitoneal mitoxantrone This treatment concept has been largely supplanted because of the clinical efficacy of imatinib. Along with hepatic arterial chemoembolization: Reserved for tumor resistant STI571 Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
108 ACGME: 5 Chemotherapy: Metastatic/Recurrent Disease Crosby JA et al. Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database. Annals of Surgical Oncology, 8(1) 2001:50 59
109 ACGME: 5 Gleevec: Metastatic/Recurrent Disease STI571 (Gleevec ) Oral Tyrosine Kinase Inhibitor Activity against Abl, Bcr-Abl, KIT, PDGFR Phase I testing demonstrated efficacy of the agent in GIST at a dose of 400 mg twice daily. Toxicities: Dose dependent Nausea 18% Vomiting 18% Edema 25% Rash 13% Intramural Bleeding 8% Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
110 ACGME: 5 Gleevec: Metastatic/Recurrent Disease Phase I Trial Gleevec (400mg BID) Well tolerated Phase II Trials US-Finland Study Group 400 mg vs. 600 mg in GIST EORTC mg daily in GIST vs. non-gist Max dose tolerated was 400 mg BID Response Evaluation Criteria in Solid Tumors (RECIST) - Multi-slice CT is considered to be the imaging modality of choice to assess response. (3 month intervals) -PET imagingstandard for the future Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005) Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
111 ACGME: 5 Gleevec: Metastatic/Recurrent Disease Phase III Trials Two International Trials assessed 400 mg QD to 400 mg BID North American Sarcoma Intergroup (S0033) European Organization for Research & Treatment Cancer (EORTC) No statistical difference in the overall survival & progression free survival Side effects are higher in second group but less when started at 400 mg daily & then advanced to twice daily Recommended dose Initial therapy: 400mg daily Lack of response/progression: 400mg twice daily French Sarcoma Group Trial looked at duration of therapy Continuous treatment better than interrupted temporarily Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005) Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
112 ACGME: 5 Gleevec: Metastatic/Recurrent Disease Response rate with Daily dose of mg 48-54% Disease stabilization & Minor remission 20-35% Median Time to Progression 19 Months Median duration of remission 27 Months Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005) Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
113 ACGME: 5 Gleevec: Metastatic/Recurrent Disease Type of Mutation: KIT/PDGFR response to Gleevec The median event-free survival Wild type PDGFRα mutation 82 days Exon 9 mutation 29 weeks Exon 11 mutation 98 weeks 5 year recurrence free survival 89% (Exon11) 40 % (Other Kit Mutations) Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005)
114 ACGME: 5 Gleevec: Problems?? Resistance to STI571 Treatment Options: Dose Escalation Cross over to 400mg BID: Improved disease stabilization Local treatments Radiofrequency or Laser ablation Surgical Resection General Progression Despite of STI571 New Tyrosine Kinase Inhibitor under evaluation SU (Sunitinib, Sutent ) Multi-tyrosine kinase inhibitor with anti-angiogenetic properties Targets KIT, PDGFR & VEGFR Approved by FDA after phase III trials» Reserved for Gleevec Resistance Gupta M et al. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. J Gastrointest Surg 2006;10:
115 ACGME: 5 Newer Agents in Horizon Margaret von Mehren et al. Gastrointestinal Stromal Tumors. Hematol Oncol Clin N Am.19 (2005)
116 ACGME: 5 Role of Neoadjuvant Therapy Mainly for induction of resectability in metastatic disease Three separate studies looked at this concept Resection performed after months of Gleevec Maximum therapeutic response assessed by CT or PET scan Decreased # of viable tumor cells at time of resection» Surgical therapy in responders is valuable Pain, rupture & hemorrhage Resection Impact on survival is currently unknown Currently the RTOG-0132 is an ongoing study Gleevec 600 mg daily for 4-10 weeks preoperatively & then for 2 years postoperatively Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
117 ACGME: 5 Role of Neoadjuvant Therapy MD Anderson CC Trial 16/17 patients treated with Gleevec complete resection 2/17 patients had pathological complete response at surgery 11/17 had partial pathological response to gleevec» Variable tumor still present after therapy» Surgery remains an important part of therapy German Group 11 patients treated with Gleevec complete resection 10 patients R0 resection 6 hepatic & 5 peritoneal metastasectomy All patients alive at median follow up of 46 months Scaife CL et al. Is there a role for surgery in patients with unresectable ckit gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186: Bauer S et al. Imatinib may enable complete resection in previously unresectable or metastatic GIST. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). vol. 22, No. 14S (July 15 Supplement).
118 ACGME: 5 Adjuvant Therapy for Primary Tumors Logic for Gleevec after primary resection Risk of recurrence after surgical resection is high Chemotherapy is ineffective Gleevec works in metastatic & recurrent GIST Gleevec will have its greatest effect on survival when there is minimal disease Currently under investigational studies in North America and Europe Two studies (ACOSOG-Z9000 & ACOSOG-Z9001) Results will be available in 2007! Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
119 ACGME: 5 Adjuvant Therapy for Primary Tumors ACOSOG-Z9000 (Phase II trial) in sponsorship by Cancer Therapy Evaluation Program & Novartis Testing 400 mg/day for 1 yr after complete resection in patients with high risk primary GIST High Risk Tumor size > 10cm Tumor Rupture Tumor Hemorrhage Multifocal (>5) tumors Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
120 ACGME: 5 Adjuvant Therapy for Primary Tumors ACOSOG Z9001 (Phase III trial) in sponsorship by Cancer Therapy Evaluation Program & Novartis STI mg/day vs. Placebo for 1 yr after complete resection in patients with GIST 3 cm Double-Blinded Randomized Trial Placebo arm will cross over in case of recurrent GIST Primary end point is survival between the two arms Eisenberg et al. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol, 11(5) 2004;
121 ACGME: 5 Adjuvant Therapy for Primary Tumors ACOSOG-Z9000 ACOSOG-Z9001
122 ACGME: 5 Current Recommendations Operable GIST Surgery: Complete Resection Gleevec Incomplete resection Tumor spillage High-risk factors For marginally resectable GISTs or in cases of operable recurrent or metastatic GIST Clinical trial of Gleevec Surgical Resection Gupta M et al. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. J Gastrointest Surg 2006;10:
123 ACGME: 5
124 ACGME: 5
National Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationInternational Journal of Scientific & Engineering Research, Volume 7, Issue 5, May ISSN Case Report Rare Case Of Small Bowel GIST
International Journal of Scientific & Engineering Research, Volume 7, Issue 5, May-2016 282 Case Report Rare Case Of Small Bowel GIST Shahaji G. Chavan, Sagar R. Ambre, Vinayak kshirsagar, Ashish Vashistha
More informationRADIOFREQUENCY ABLATION
RADIOFREQUENCY ABLATION ELIZABETH DAVID M D FRCPC VASCULAR A ND INTERVENTIONAL RADIOLOGIST SUNNYBROOK HEALTH SCIENCES CENTRE GIST GASTROINTESTINAL STROMAL TUMORS Stromal or mesenchymal neoplasms affecting
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationImaging of Gastrointestinal Stromal Tumors (GIST) Amir Reza Radmard, MD Assistant Professor Shariati hospital Tehran University of Medical Sciences
Imaging of Gastrointestinal Stromal Tumors (GIST) Amir Reza Radmard, MD Assistant Professor Shariati hospital Tehran University of Medical Sciences Describe the typical imaging findings of GIST at initial
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationEvaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment
The Open Pathology Journal, 2009, 3, 53-57 53 Open Access Evaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment Katie L. Dennis * and Ivan Damjanov Department of Pathology
More informationBrief History. Identification : Past History : HTN without regular treatment.
Brief History Identification : Name : 陳 x - Admission : 94/10/06 Gender : male Age : 75 y/o Chief Complaint : Urinary difficulty for months. Past History : HTN without regular treatment. Brief History
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Malignant Gastrointestinal Stromal tumor of the Sigmoid Colon with Perforation and Peritonitis - an Unusual
More informationClinicopathologic Spectrum of Gastrointestinal Stromal Tumours; Six Years Experience at King Hussein Medical Center
Clinicopathologic Spectrum of Gastrointestinal Stromal Tumours; Six Years Experience at King Hussein Medical Center Sahem T. Alqusous MD*, Osama J. Rabadi MD, MRCS*, Ala D. Al Omari MD*, Nabeeha N.Abbasi
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationGastrointestinal Stromal Tumor Case Presentations
Gastrointestinal Stromal Tumor Case Presentations Ricardo J. Gonzalez, MD Professor of Surgery Chair, Sarcoma Department Chief of Surgery Moffitt Cancer Center Patient number 1 64 yo male with upper abdominal
More informationMalignant gastrointestinal stromal (GISTs) of the duodenum A rare occurrence: Case report
Malignant gastrointestinal stromal tumors (GISTs) of the duodenum Case Report ISSN: 2394-0026 (P) Malignant gastrointestinal stromal tumors (GISTs) of the duodenum A rare occurrence: Case report Kandukuri
More informationMulti-cystic gist of stomach: an unusual presentation as obstructive jaundice.
Multi-cystic gist of stomach: an unusual presentation as obstructive jaundice. Dr. Kirankumar P. Jadhav *, Prof. Dr. Sanjiv S. Thakur**Prof. Dr. Ajay S. Chandanwalle*** Dr. Schin M. Kharat****, Dr. Chhaya
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationCase Presentation: GIST
Case Presentation: GIST 9 th Annual Clinical Cancer Update Conference Squaw Creek, North Lake Tahoe January 2010 Anne Espinoza, M.D. Hematology/Oncology Fellow University of California, San Francisco Initial
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
GIST (Gastrointestinal stromal tumor) Updated MARCH 2017 by Dr. Doreen Ezeife, PGY-5 Resident, University of Calgary Reviewed by Dr. Jan-Willem Henning (Staff Medical Oncologist, University of Calgary)
More informationSubepithelial Lesions of the Gut: When Should I Worry?
Subepithelial Lesions of the Gut: When Should I Worry? President, ASGE Chairman, GI & Hepatology Scottsdale, AZ Faigel.douglas@mayo.edu Case 55 yo male with reflux EGD for Barrett s Screening SET, mucosal
More informationMesenchymal neoplasms of the gastrointestinal tract what s new? Newton ACS Wong Department of Histopathology Bristol Royal Infirmary
Mesenchymal neoplasms of the gastrointestinal tract what s new? Newton ACS Wong Department of Histopathology Bristol Royal Infirmary Talk plan Summary from 2010 talk. What s happened since 2010. GISTs
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY
GOAL: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY 1. Understated the role of cytopathology in the clinical management of the patient and recognize
More informationCase Report Unusual Appearance of a Pendulated Gastric Tumor: Always Think of GIST
Case Reports in Surgery Volume 2012, Article ID 815941, 4 pages doi:10.1155/2012/815941 Case Report Unusual Appearance of a Pendulated Gastric Tumor: Always Think of GIST Kristel De Vogelaere, 1 Vanessa
More informationImages In Gastroenterology
Images In Gastroenterology Thong-Ngam D, et al. THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 105 Imaging of Gastrointestinal Stromal Tumors Pornpim Fuangtharnthip, M.D. Narumol Hargroove, M.D.
More informationGastrointestinal Stromal Tumors: challenges in diagnosis and treatment
Gastrointestinal Stromal Tumors: challenges in diagnosis and treatment Waleed Hammam Mosa (1) Abdelmoiem Mourad (2) Reem Ashery (2) Ibrahim Abdelkader Salama (3) (1) Department of Clinical Oncology, Faculty
More informationGiant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib
Int Canc Conf J (2012) 1:41 46 DOI 10.1007/s13691-011-0007-9 CASE REPORT Giant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib Kaori Shigemitsu Takako Yamada Shinichiro
More informationAbstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
More informationGlivec en KIT: immuunhistochemie en mutatie analyse in gastro-intestinale stromacel tumoren. Judith V.M.G. Bovee Patholoog LUMC
Glivec en KIT: immuunhistochemie en mutatie analyse in gastro-intestinale stromacel tumoren Judith V.M.G. Bovee Patholoog LUMC Case 60 year old female Pain and discomfort upper abdomen MRI: tumor small
More informationANTICANCER RESEARCH 28: (2008)
Comparative Analysis of Four Histopathological Classification Systems to Discriminate Benign and Malignant Behaviour in Gastrointestinal Stromal Tumors D. VALLBÖHMER 1, H.E. MARCUS 1, S.E. BALDUS 2, J.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationGastrointestinal stromal tumours - clinicopathological study
Original research article Gastrointestinal stromal tumours - clinicopathological study *Dr. Putrevu Venkata Gurunadha Raju, ** Dr. Kanwaljit Kaur *Professor, **Assistant Professor Department of Pathology,
More informationGastrointestinal stromal tumors from a poorly defined pathologic oddity to a milestone in solid tumor oncology
Mædica - a Journal of Clinical Medicine EDITORIALS Gastrointestinal stromal tumors from a poorly defined pathologic oddity to a milestone in solid tumor oncology Lucian MIRON, MD, PhD, Ingrith MIRON, MD,
More informationUnderstanding Your GIST Pathology Report
Gastrointestinal Stromal Tumor Understanding Your GIST Pathology Report Jason L. Hornick, MD PhD Harvard Medical School Brigham and Women's Hospital Alexander J.F. Lazar, MD PhD Sarcoma Research Center
More informationUpdate on the Biology and Therapy of Gastrointestinal Stromal Tumors
The biology and treatment of gastrointestinal sarcomas are reviewed, as well as the status of targeted therapy for these tumors. Dorothy Fox. The Weaver. Watercolor, 30 36. Update on the Biology and Therapy
More informationClinical Analysis of Diagnosis and Treatment of Gastrointestinal Stromal Tumors (Report of 96 Cases)
121 Clinical Analysis of Diagnosis and Treatment of Gastrointestinal Stromal Tumors (Report of 96 Cases) Yueliang Lou Xieliang Zhang Hua Chen Zhongli Zhan Cancer Hospital of Tianjin Medical University,
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationGastrointestinal Stromal Tumors: Epidemiology and Treatment Outcomes
Gastrointestinal Stromal Tumors: Epidemiology and Treatment Outcomes Original Article Peyvandi H 1, Haji Nasrollah E 2, Mousavian SA 3, Daryaii P 4, Yeganeh R 2, Davati A 5, Ghanei GR 6 Abstract Introduction:
More informationEvolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010
Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010 Molecular mechanisms for cancer Prevention and screening Molecular
More informationCase Report Esophageal Gastrointestinal Stromal Tumor: Diagnostic Complexity and Management Pitfalls
Case Reports in Surgery Volume 2013, Article ID 968394, 4 pages http://dx.doi.org/10.1155/2013/968394 Case Report Esophageal Gastrointestinal Stromal Tumor: Diagnostic Complexity and Management Pitfalls
More informationAnalysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
Ann Surg Oncol DOI 10.1245/s10434-014-3632-7 ORIGINAL ARTICLE BONE AND SOFT TISSUE SARCOMAS Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy
More informationOriginal Article. Keywords: Gastrointestinal stromal tumors (GIST); KIT; tyrosine kinase inhibitors (TKIs); immunohistochemical staining
Original Article Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico Abdel Karim Dip Borunda,
More informationSoft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee
Soft Tissue Sarcoma Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee Soft Tissue Sarcoma Collective term for an unusual and diverse
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationRare GI Malignancies
Rare GI Malignancies Jordan Karlitz, MD Associate Professor of Medicine, Division of Gastroenterology Director, Hereditary GI Cancer and Genetics Program Tulane University School of Medicine Outline Gastrointestinal
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationClinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 212067, 5 pages doi:10.1155/2008/212067 Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
More informationImatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs
Original Article Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs Chunmeng Wang, Biqiang Zheng, Yong Chen, Xi Cao, Ruming Zhang, Yingqiang Shi Gastric Cancer and
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationGIST 101: The Biology of GIST
GIST 101: The Biology of GIST David Josephy University of Guelph david.josephy@liferaftgroup.ca Disclaimer: I am not a physician. I am a biochemist with some experience in cancer research. What is GIST?
More informationIMATINIB MESYLATE THERAPY IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EXPERIENCE FROM A SINGLE INSTITUTE
IMATINIB MESYLATE THERAPY IN ADVANCED GASTRINTESTINAL STRMAL TUMRS: EXPERIENCE FRM A SINGLE INSTITUTE Hui-Hua Hsiao, 1,2 Yi-Chang Liu, 2 Hui-Jen Tsai, 2 Li-Tzong Chen, 1,2 Ching-Ping Lee, 2 Chieh-Han Chuan,
More informationLeiomyosarcoma of the inferior vena cava: 1 case. B. Bancel, A. Rode, C. Ducerf. Hôpital CROIX ROUSSE LYON. Case report
Leiomyosarcoma of the inferior vena cava: 1 case B. Bancel, A. Rode, C. Ducerf Hôpital CROIX ROUSSE LYON Bucharest Nov 2011 Case report 34 yr-old woman, no antecedent Sept 2004: Abdominal upper right quadrant
More informationManagement of gastrointestinal stromal tumors: A 10-year experience of a single surgical department
Original papers Management of gastrointestinal stromal tumors: A 1-year experience of a single surgical department Dariusz Janczak 1,2,A,F, Jacek Rać 1,B,D, Wiktor Pawłowski 1,2,A,D, Tadeusz Dorobisz 1,3,C,E,
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationProtocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor (GIST)
Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor (GIST) Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging
More informationYasumasa MONOBE 1), Yoshio NAOMOTO 2), Jiro HAYASHI 2), Tomoki YAMATSUJI 2), Yoshito SADAHIRA 3)
Kawasaki Medical Journal 43(1):5 12,2017 doi:10.11482/kmj-e43(1)5 5 Case Report A case of gastrointestinal stromal tumor (GIST) with peritoneal dissemination - Imatinib re-challenged case - Yasumasa MONOBE
More informationIntussuception due to gastrointestinal stromal tumor with neural differentiation in a patient with. Von Recklinghausen Neurofibromatosis,
Turkish Journal of Cancer Vol 31/ No.4 /2001 Intussuception due to gastrointestinal stromal tumor with neural differentiation in a patient with Von Recklinghausen Neurofibromatosis (NF-1): A case report
More informationAffiliazione autori0. Riccardo Ricci Journal Club GIPAD, settore GIST Anatomia Patologica, Università Cattolica, Roma
GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases American Journal of Surgical Pathology, 2017, 41:577-585 Miettinen M*; Felisiak-Golabek
More informationWilms Tumor and Neuroblastoma
Wilms Tumor and Neuroblastoma Wilm s Tumor AKA: Nephroblastoma the most common intra-abdominal cancer in children. peak incidence is 2 to 3 years of age Biology somatic mutations restricted to tumor tissue
More informationGastrointestinal Stromal Tumor
TAJ June 2009; Volume 22 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review Article Gastrointestinal Stromal Tumor P K Biswas * Abstract Gastrointestinal stromal tumors (GISTs)
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationGastrointestinal Stromal Tumor Surgery and Adjuvant Therapy
Gastrointestinal Stromal Tumor Surgery and Adjuvant Therapy Valerie P. Grignol, MD a, Paula M. Termuhlen, MD b, * KEYWORDS GIST Gastrointestinal stromal tumor KIT PDGFRA Imatinib mesylate Gastrointestinal
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationRadio-Pathologic Workup of a Retroperitoneal Abdominal Mass
Radio-Pathologic Workup of a Retroperitoneal Abdominal Mass Joe Carlson Advanced Radiology Clerkship Harvard Medical School Year IV September 12, 2002 84 year old Male Presented to PCP With Abdominal Pain
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationGASTROINTESTINAL STROMAL TUMORS: CLINICAL, IMMUNOHISTOCHEMICAL, TREATMENT ASPECTS AND PREDICTORS OF SURVIVAL
GASTROINTESTINAL STROMAL TUMORS: CLINICAL, IMMUNOHISTOCHEMICAL, TREATMENT ASPECTS AND PREDICTORS OF SURVIVAL *Mohit Sharma Department of Surgery, Sri Guru Ramdass Institute of Medical Science and Research,
More informationMorphological Features of Metastatic Gastrointestinal Stromal Tumors after Gleevec Treatment
The Korean Journal of Pathology 2009; 43: 368-73 DOI: 10.4132/KoreanJPathol.2009.43.4.368 Morphological Features of Metastatic Gastrointestinal Stromal Tumors after Gleevec Treatment - Two Cases Report
More informationA giant primary omental extragastrointestinal tumor: A case report
Mir et al. 1 CASE REPORT PEER REVIEWED OPEN ACCESS A giant primary omental extragastrointestinal tumor: A case report Ruquaya Mir, Vikram P. Singh, Sumaid Kaul ABSTRACT Extragastrointestinal stromal tumor
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationCase: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on
Case: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on imaging. There is no significant past medical history.
More informationLocally Advanced Colon Cancer. Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery
Locally Advanced Colon Cancer Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery Case 34 yo man presented with severe RLQ abdominal pain X 24 hrs. No nausea/vomiting/fever. + flatus.
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationImaging Gastrointestinal Stromal Tumors
The imaging features of nonmetastasizing and malignant gastrointestinal stromal tumors are reviewed. Fishing boats, Mytho, Mekong Delta,Vietnam. Photograph courtesy of J. Bryan Murphy, MD, Clearwater,
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationManagement of Cholangiocarcinoma. Roseanna Lee, MD PGY-5 Kings County Hospital
Management of Cholangiocarcinoma Roseanna Lee, MD PGY-5 Kings County Hospital Case Presentation 37 year old male from Yemen presented with 2 week history of epigastric pain, anorexia, jaundice and puritis.
More informationChristopher Lau Kings County Hospital SUNY Downstate Medical Center February 24, 2011
Christopher Lau Kings County Hospital SUNY Downstate Medical Center February 24, 2011 37 year old male presented with 1 day history of abdominal pain Pain was diffuse but worst in the epigastric area No
More informationBy Prof. Mohamed Khaled Zaky, MB,BCh; MSc; MD; FRCSI (Gen. Surg.) Professor of Surgery, Taibah Univ.
By Prof. Mohamed Khaled Zaky, MB,BCh; MSc; MD; FRCSI (Gen. Surg.) Professor of Surgery, Taibah Univ. Objectives Types Incidence Risk factors (& prevention) Pathology: Gross, microscopic, spread, staging,
More informationUpper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012
Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Version Control This is a controlled document please destroy all previous versions on receipt
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More information59 yo male with past medical history of prostate carcinoma, presented with upper abdominal pain
December 2016 59 yo male with past medical history of prostate carcinoma, presented with upper abdominal pain Contributed by: Divya Sharma, MD. Fellow, Gastrointestinal Pathology, Department of Pathology
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationBone metastasis of a gastrointestinal stromal tumor: A report of two cases
1814 Bone metastasis of a gastrointestinal stromal tumor: A report of two cases KAYO SUZUKI 1, TAKETOSHI YASUDA 1, KAORU NAGAO 2, TAKESHI HORI 2, KENTA WATANABE 1, MASAHIKO KANAMORI 3 and TOMOATSU KIMURA
More informationUncommon secondary tumour of the stomach
Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationPlease complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
More informationSurgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School
Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum
More informationأملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5
Leiomyosarcoma 1 / 5 EPIDEMIOLOGY Exact incidence is unknown, but older studies suggest that leiomyosarcomas comprise approximately 3 percent of soft-tissue sarcomas. Superficial leiomyosarcoma occurs
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationAdvanced or Metastatic Gastrointestinal Stromal Tumors: Systemic Treatment Options
2011;104:888 895 Advanced or Metastatic Gastrointestinal Stromal Tumors: Systemic Treatment Options MEGAN V. CARAM, MD AND SCOTT M. SCHUETZE, MD, PhD* Division of Hematology/Oncology, Department of Internal
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Adjuvant imatinib after complete resection of primary gastrointestinal stromal tumour (GIST) in patients at high risk of relapse May 2012 Summary NICE guidance
More information